4.6 Article

The transcriptional repressor BCL11A promotes breast cancer metastasis

期刊

JOURNAL OF BIOLOGICAL CHEMISTRY
卷 295, 期 33, 页码 11707-11719

出版社

ELSEVIER
DOI: 10.1074/jbc.RA120.014018

关键词

breast cancer; metastasis; invasion; transcription; alternative splicing; B-cell leukemia; lymphoma 11A (BCL11A); muscleblind-like splicing regulator 1 (MBNL1); integrin-alpha 6 (ITGA6); gene regulation; gene transcription

资金

  1. Department of Defense [W81XWH-14-1-0354]
  2. NIH [R01 CA206505]
  3. Clinical and Translational Science Collaborative of Cleveland [KL2 TR000440]
  4. University Hospitals Department of Medicine Team Science Award 2014
  5. Genomics Core Facility of the CWRU School of Medicine's Genetics and Genome Sciences Department

向作者/读者索取更多资源

The phenotypes of each breast cancer subtype are defined by their transcriptomes. However, the transcription factors that regulate differential patterns of gene expression that contribute to specific disease outcomes are not well understood. Here, using gene silencing and overexpression approaches, RNA-Seq, and splicing analysis, we report that the transcription factor B-cell leukemia/lymphoma 11A (BCL11A) is highly expressed in triple-negative breast cancer (TNBC) and drives metastatic disease. Moreover, BCL11A promotes cancer cell invasion by suppressing the expression of muscleblind-like splicing regulator 1 (MBNL1), a splicing regulator that suppresses metastasis. This ultimately increases the levels of an alternatively spliced isoform of integrin-alpha 6 (ITGA6), which is associated with worse patient outcomes. These results suggest that BCL11A sustains TNBC cell invasion and metastatic growth by repressing MBNL1-directed splicing ofITGA6. Our findings also indicate that BCL11A lies at the interface of transcription and splicing and promotes aggressive TNBC phenotypes.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.6
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

Article Oncology

Sexually dimorphic radiogenomic models identify distinct imaging and biological pathways that are prognostic of overall survival in glioblastoma

Niha Beig, Salendra Singh, Kaustav Bera, Prateek Prasanna, Gagandeep Singh, Jonathan Chen, Anas Saeed Bamashmos, Addison Barnett, Kyle Hunter, Volodymyr Statsevych, Virginia B. Hill, Vinay Varadan, Anant Madabhushi, Manmeet S. Ahluwalia, Pallavi Tiwari

Summary: This study identified sexually dimorphic radiogenomic models that could be used to help with personalized treatment decisions for GBM patients by revealing biological changes and prognostic differences between different genders.

NEURO-ONCOLOGY (2021)

Article Genetics & Heredity

Comprehensive characterization of protein-protein interactions perturbed by disease mutations

Feixiong Cheng, Junfei Zhao, Yang Wang, Weiqiang Lu, Zehui Liu, Yadi Zhou, William R. Martin, Ruisheng Wang, Jin Huang, Tong Hao, Hong Yue, Jing Ma, Yuan Hou, Jessica A. Castrillon, Jiansong Fang, Justin D. Lathia, Ruth A. Keri, Felice C. Lightstone, Elliott Marshall Antman, Raul Rabadan, David E. Hill, Charis Eng, Marc Vidal, Joseph Loscalzo

Summary: Recent advancements in genomics and interactomics have allowed researchers to identify how disease mutations disrupt protein-protein interaction networks within human cells. Disease-associated germline variants and somatic missense mutations are significantly enriched in protein-protein interaction interfaces, and oncoPPIs identified in cancer analysis are correlated with patient survival and drug resistance/sensitivity. Experimental validation of oncoPPIs and their effects on tumor cell growth demonstrate the potential of using this interactome network framework for prioritizing therapeutic targets.

NATURE GENETICS (2021)

Article Biochemistry & Molecular Biology

TGF-β/activin signaling promotes CDK7 inhibitor resistance in triple-negative breast cancer cells through upregulation of multidrug transporters

Bryan M. Webb, Benjamin L. Bryson, Eduardo Williams-Medina, Jessica R. Bobbitt, Darcie D. Seachrist, Lindsey J. Anstine, Ruth A. Keri

Summary: This study reveals that inhibiting the TGF-beta/Activin-ABCG2 pathway is a potential avenue for preventing or overcoming resistance to CDK7 inhibitors.

JOURNAL OF BIOLOGICAL CHEMISTRY (2021)

Article Multidisciplinary Sciences

ICAM1 initiates CTC cluster formation and trans-endothelial migration in lung metastasis of breast cancer

Rokana Taftaf, Xia Liu, Salendra Singh, Yuzhi Jia, Nurmaa K. Dashzeveg, Andrew D. Hoffmann, Lamiaa El-Shennawy, Erika K. Ramos, Valery Adorno-Cruz, Emma J. Schuster, David Scholten, Dhwani Patel, Youbin Zhang, Andrew A. Davis, Carolina Reduzzi, Yue Cao, Paolo D'Amico, Yang Shen, Massimo Cristofanilli, William A. Muller, Vinay Varadan, Huiping Liu

Summary: CTC clusters are more efficient in mediating metastasis and ICAM1 may be a novel therapeutic target for the initiation of TNBC metastasis.

NATURE COMMUNICATIONS (2021)

Article Oncology

Multi-scale Pan-cancer Integrative Analyses Identify the STAT3-VSIR Axis as a Key Immunosuppressive Mechanism in Head and Neck Cancer

Ramachandra Katabathula, Peronne Joseph, Salendra Singh, Songzhu Zhao, Bhavna Kumar, Patricia Gaule, Quintin Pan, Matthew Old, David P. Tuck, Vinay Varadan

Summary: This study investigated the expression and clinical significance of VSIR in tumors. It found that VSIR overexpression in oral cavity and ovarian cancers was associated with poorer overall survival and decreased CD4 helper T-cell activity. VSIR overexpressing tumors also exhibited higher STAT3 signaling activity. The findings suggest that the STAT3-VSIR axis may play a significant role in the immune response of these types of cancer.

CLINICAL CANCER RESEARCH (2022)

Review Endocrinology & Metabolism

Centrosome Aberrations as Drivers of Chromosomal Instability in Breast Cancer

Katrina M. Piemonte, Lindsey J. Anstine, Ruth A. Keri

Summary: Chromosomal instability (CIN) plays a crucial role in cancer, with centrosome defects being a key factor contributing to CIN. Breast cancer patients often exhibit centrosome defects, which can drive genomic changes in cancer cells, leading to aggressive disease and poor outcomes.

ENDOCRINOLOGY (2021)

Review Oncology

FOXA1: A Pioneer of Nuclear Receptor Action in Breast Cancer

Darcie D. Seachrist, Lindsey J. Anstine, Ruth A. Keri

Summary: The review discusses the role of FOXA1 in regulating gene activity, cell biology, and the response of breast cancers to hormone therapies. It also highlights the potential for future studies to explore the roles of FOXA1 independent of its regulation of nuclear receptors.

CANCERS (2021)

Article Biochemical Research Methods

SYSMut: decoding the functional significance of rare somatic mutations in cancer

Sirvan Khalighi, Peronne Joseph, Deepak Babu, Salendra Singh, Thomas LaFramboise, Kishore Guda, Vinay Varadan

Summary: SYSMut is an extendable systems biology platform that can infer the biological consequences of gene mutations by integrating multiomics profiles. It has been used to identify driver genes across 29 cancers and discover new therapeutic targets in head and neck squamous cell cancer.

BRIEFINGS IN BIOINFORMATICS (2022)

Article Gastroenterology & Hepatology

The Ephrin B2 Receptor Tyrosine Kinase Is a Regulator of Proto-oncogene MYC and Molecular Programs Central to Barrett's Neoplasia

Srividya Venkitachalam, Deepak Babu, Durgadevi Ravillah, Ramachandra M. Katabathula, Peronne Joseph, Salendra Singh, Bhavatharini Udhayakumar, Yanling Miao, Omar Martinez-Uribe, Joyce A. Hogue, Adam M. Kresak, Dawn Dawson, Thomas LaFramboise, Joseph E. Willis, Amitabh Chak, Katherine S. Garman, Andrew E. Blum, Vinay Varadan, Kishore Guda

Summary: The study suggests that the EphB2 signaling pathway is frequently hyperactivated in the early development of Barrett's esophagus-associated esophageal adenocarcinoma (BE-EAC) and acts as an upstream regulator of the MYC gene. Inhibiting EphB2 can significantly impede the proliferation of BE and EAC cells. Targeting EphB2/MYC could be a promising strategy for treating this common refractory and aggressive cancer.

GASTROENTEROLOGY (2022)

Letter Gastroenterology & Hepatology

HNF4A Defines Molecular Subtypes and Vulnerability to Transforming Growth Factor β-Pathway Targeted Therapies in Cancers of the Distal Esophagus

Andrew E. Blum, Durgadevi Ravillah, Ramachandra M. Katabathula, Sirvan Khalighi, Vinay Varadan, Kishore Guda

GASTROENTEROLOGY (2022)

Article Oncology

Focal Adhesion Kinase Provides a Collateral Vulnerability That Can Be Leveraged to Improve mTORC1 Inhibitor Efficacy

Leslie Cuellar-Vite, Kristen L. Weber-Bonk, Fadi W. Abdul-Karim, Christine N. Booth, Ruth A. Keri

Summary: This study discovered that blocking FAK can improve the therapeutic response to mTORC1 inhibitors in resistant breast cancer. It suggests a potential strategy of dual targeting FAK and mTORC1.

CANCERS (2022)

Article Oncology

TLE3 Sustains Luminal Breast Cancer Lineage Fidelity to Suppress Metastasis

Lindsey J. Anstine, Parth R. Majmudar, Amy Aponte, Salendra Singh, Ran Zhao, Kristen L. Weber-Bonk, Fadi W. Abdul-Karim, Mitchell Valentine, Darcie D. Seachrist, Katelyn E. Grennel-Nickelson, Leslie Cuellar-Vite, Gina M. Sizemore, Steven T. Sizemore, Bryan M. Webb, Cheryl L. Thompson, Ruth A. Keri

Summary: Breast cancer subtypes and their phenotypes correspond to different stages of mammary epithelial cell development. The discovery of mechanisms that control lineage identity may offer new opportunities for reducing disease progression. This study reveals that the transcriptional corepressor TLE3 functions as a guardian of luminal cell fate in breast cancer, independent of the estrogen receptor. TLE3 represses the gene-expression signature associated with aggressive basal-like breast cancers, thereby reducing metastatic capacity and aggressive behaviors.

CANCER RESEARCH (2023)

Review Endocrinology & Metabolism

Chromatin Organization and Transcriptional Programming of Breast Cancer Cell Identity

Jessica R. Bobbitt, Darcie D. Seachrist, Ruth A. Keri

Summary: The development of sequencing technologies has provided valuable information about the organization of the 3-dimensional genome and its influence on cancer progression. Chromatin folding and accessibility changes can lead to abnormal transcriptional programs and drive the development of various cancers, including different subtypes of breast cancer. Understanding the chromatin architecture in breast cancer subtypes can help define their phenotypic characteristics and identify potential targets for aggressive disease treatment.

ENDOCRINOLOGY (2023)

Article Medicine, Research & Experimental

Eltrombopag inhibits TET dioxygenase to contribute to hematopoietic stem cell expansion in aplastic anemia

Yihong Guan, Metis Hasipek, Dongxu Jiang, Anand D. Tiwari, Dale R. Grabowski, Simona Pagliuca, Sunisa Kongkiatkamon, Bhumika Patel, Salendra Singh, Yvonne Parker, Thomas LaFramboise, Daniel Lindner, Mikkael A. Sekeres, Omar Y. Mian, Yogen Saunthararajah, Jaroslaw P. Maciejewski, Babal K. Jha

Summary: Eltrombopag binds to the TET2 catalytic domain and inhibits its dioxygenase activity, leading to the expansion of normal hematopoietic stem cells and the prevention of neoplastic evolution in TET2 mutant malignant myeloid cells. This finding provides a scientific rationale for the treatment of myeloid malignancies associated with TET2 mutations or TET deficiency.

JOURNAL OF CLINICAL INVESTIGATION (2022)

Article Biochemistry & Molecular Biology

ITGA2 promotes expression of ACLY and CCND1 in enhancing breast cancer stemness and metastasis

Valery Adorno-Cruz, Andrew D. Hoffmann, Xia Liu, Nurmaa K. Dashzeveg, Rokana Taftaf, Brian Wray, Ruth A. Keri, Huiping Liu

Summary: The study revealed that miR-206 inhibits ITGA2 to reduce breast cancer stemness and metastasis. Knockdown of ITGA2 suppressed self-renewal, cell cycling, migration, invasion, and lung metastasis, related to CCND1 and ACLY.

GENES & DISEASES (2021)

暂无数据